August 12, 2024:

The Big Ten Cancer Research Consortium is happy to celebrate the research accomplishments of our members over the past year. Congratulations to all researchers and study teams whose hard work produced eight journal manuscripts and meeting abstracts between July 1, 2023, and June 30, 2024!

Journal Manuscripts

BTCRC-GU16-043: Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study

  • Journal: Nature Communications (February 2024)
  • Link: https://www.nature.com/articles/s41467-024-45216-z
  • Authors: Yousef Zakharia, Eric A. Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette, Ilona Kryczek, Weiping Zou, Ajjai Alva

BTCRC-HEM15-027: JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma.

  • Journal: Science (June 2024)
  • Link: https://www.science.org/doi/10.1126/science.ade8520#Fa
  • Authors: Jaroslav Zak, Isaraphorn Pratumchai, Brett Marro, Kristi Marquardt, Reza Beheshti Zavareh, Luke Lairson, Michael Oldstone, Judith Varner, Livia Hegerova, Qing Cao, Umar Farooq, Vaishalee Kenkre, Veronika Bachanova, John Teijaro

Big Ten CRC Population Science Working Group: Translating catchment area cancer burden into metrics using the logic model: Insights from the Population Science Working Group of the Big 10 Cancer Research Consortium

  • Journal: Preventive Oncology & Epidemiology
  • Link: https://www.tandfonline.com/doi/full/10.1080/28322134.2023.2298086
  • Authors: Sharon L. Manne, Victoria Champion, Marian Fitzgibbon, Anita Y. Kinney, Cheryl Knott, Eugene J. Lengerich, Sarah Nash, Melissa Simon, Marquita W. Lewis-Thames, Amy Trentham-Dietz, Chasity Washington, Shinobu Watanabe-Galloway, Electra D. Paskett, Margaret Wright Geise

Meeting Abstracts

BTCRC-BRE18-337: Phase 2 trial with safety-run in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive HER2 negative breast cancer.

BTCRC-GI22-564: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC).

BTCRC-LUN16-081: Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC

BTCRC-LUN17-127: Phase II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC)

  • Abstract Type: Poster
  • Meeting: Society for Immunotherapy of Cancer (November 2023)
  • Abstract URL: https://jitc.bmj.com/content/11/Suppl_1/A686
  • Authors: Jyoti Malhotra, Alberto Chiappori, Naomi Fujioka, Nasser H Hanna, Lawrence E Feldman5, Malini Patel, Dirk Moore, Chunxia Chen, Salma K Jabbour

BTCRC-LUN18-153: A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm

  • Abstract Type: Trials in Progress
  • Meeting: ASCO (June 2024)
  • Abstract URL: https://meetings.asco.org/abstracts-presentations/238538
  • Authors: Greg Andrew Durm, Muhammad Furqan, Richard Delmar Hall, Alberto Chiappori, Patrick C. Ma, Lawrence Eric Feldman, Amit Kulkarni, Missak Haigentz, Apar Kishor Ganti, Dwight Hall Owen, Rachel E. Sanborn, Nasser H. Hanna

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.